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Abstract
The scavenger receptor MARCO mediates macrophage recognition and clearance of pathogens and their polyanionic
ligands. However, recent studies demonstrate MARCO expression and function in dendritic cells, suggesting MARCO might
serve to bridge innate and adaptive immunity. To gain additional insight into the role of MARCO in dendritic cell activation
and function, we profiled transcriptomes of mouse splenic dendritic cells obtained from MARCO deficient mice and their
wild type counterparts under resting and activating conditions. In silico analysis uncovered major alterations in gene
expression in MARCO deficient dendritic cells resulting in dramatic alterations in key dendritic cell-specific pathways and
functions. Specifically, changes in CD209, FCGR4 and Complement factors can have major consequences on DC-mediated
innate responses. Notably, these perturbations were magnified following activation with the TLR-4 agonist
lipopolysaccharide. To validate our in silico data, we challenged DC‘s with various agonists that recognize all mouse
TLRs and assessed expression of a set of immune and inflammatory marker genes. This approach identified a differential
contribution of MARCO to TLR activation and validated a major role for MARCO in mounting an inflammatory response.
Together, our data demonstrate that MARCO differentially affects TLR-induced DC activation and suggest targeting of
MARCO could lead to different outcomes that depend on the inflammatory context encountered by DC.
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Introduction
Scavenger receptors (SR) serve as molecular sensors on
numerous cell types. Despite considerable progress in character-
izing their function, many questions remain about their role in
inflammatory and immune responses [1,2]. Several clues indicate
that SRs may influence cellular functions beyond pattern
recognition and phagocytic clearance.
One SR, Macrophage Receptor with Collagenous Structure
(MARCO), seems to have a number of immuno-modulatory
functions. Mice deficient in MARCO suffer from exacerbated
inflammatory response upon infection with Streptococcus, expo-
sure to unopsonized particulate matter, ozone inhalation and
ovalbumin challenge following sensitization, suggesting an anti-
inflammatory role of MARCO [3–7]. Along the same lines,
MARCO deficient (MARCO
2/2) mice exhibited an early
inflammatory response to influenza, characterized by rapid
neutrophil influx to the lung, which appear to be beneficial in
early resolution of influenza [8]. In contrast to these immuno-
suppressive effects, in certain settings, MARCO is also important
for immune activation. Silica induced mast cell activation,
resulting in the production of TNF-a and reactive oxygen species
(ROS) required MARCO and SR-AI/II [9]. In addition,
activation of macrophages with CpG oligonucleotides resulting
in IL-12 and nitric oxide (NO) production was dampened in
MARCO
2/2 mice, thereby indicating a pro-inflammatory role of
MARCO [10]. This pointed to possible receptor cooperativity in
directing downstream cellular events, and our work has previously
suggested that MARCO engagement may be crucial for TLR9-
mediated IL-12 production by macrophages in response to CpG
[10]. In fact, recent evidence demonstrates that TLR signaling is
finely tuned by the presence of co-receptors, notably scavenger
receptors [11–14]. However, little is known regarding the role of
MARCO in dendritic cells (DC), a cell type that bridges early
innate immune response to activation of T lymphocytes. Genome-
wide gene expression profiling of DC pulsed with tumor cell lysate
revealed MARCO as the most upregulated gene [15]. Granucci
and colleagues have shown that MARCO mediates cytoskeletal
PLOS ONE | www.plosone.org 1 August 2014 | Volume 9 | Issue 8 | e104148rearrangements promoting dendritic lamellopodia [16], a finding
that is in line with later studies showing MARCO inhibits DC
migration, with pathophysiological consequences on allergic
asthma and cancer immunotherapy [3,17]. These observations
provided sound rationale to explore the role MARCO in DC
activation following TLR engagement. Our results suggest a major
role for MARCO in regulating TLR-induced inflammatory
response and provide context for several previously reported
functions of MARCO. Taken together, our findings highlight
TLR subclass-specific role for MARCO in modulating DC
function and broadens the spectrum of MARCO contribution to
the regulation of immunity and inflammation.
Materials and Methods
Animals
Eight- to twelve-week-old mice genetically deficient in MARCO
(MARCO
2/2) were described previously [3,6,7]. Age- and sex-
matched C57BL/6 wild-type (WT) mice purchased from Charles
River Laboratories (Wilmington, MA) were used as controls. All
mice were housed in pathogen-free conditions, and all experi-
mental procedures involving animals were approved by the
Institutional Animal Care and Use Committee at Beth Israel
Deaconess Medical Center.
Discomfort and injury to animals was limited to that which was
unavoidable in the conduct of scientifically valuable research. All
personnel performing the animal procedures/manipulations/
observations described in this protocol are technically competent
and have been properly trained to ensure that no unnecessary pain
or distress was caused to the animals as a result of the procedures/
manipulations. Mice were euthanized using CO2 inhalation in a
CO2 SMART BOX.
Cell lines
The DC2.4 cell line, derived from C57BL/6 bone marrow [18],
was kindly provided by Dr. Kenneth Rock (University of
Massachusetts Medical Center, Worcester, MA). Cells were grown
in complete media comprised of DMEM, supplemented with 10%
FBS, 10 mM HEPES, 2 mM L-glutamine and 50 mg/ml genta-
micin. DC2.4 cells were maintained at 37uC in a humidified
incubator with 5% CO2. Cells were maintained via weekly passage
and utilized for experimentation at 60–80% confluency.
Isolation of splenic dendritic cells
Spleens of untreated adult mice were digested using Spleen
Dissociation Medium (Cat #07915, STEMCELL Technologies).
Dendritic cells were isolated by positive selection from the using
the EasySep Mouse CD11c Positive Selection Kit (Cat #18758,
STEMCELL Technologies). These DC are CD11c positive and
more than 90% of them express MHC-II and the costimulatory
receptors CD80 and CD86.
In vitro activation of DC with toll-like receptor agonists
Three DC pools were obtained from both MARCO
2/2 and
age- and gender-matching control C57BL/6 mice by purifying
spleen DC from 5–6 animals per pool. DC from each pool were
cultured overnight at 10
6/ml in 24-well plates in the presence or
absence of TLR agonists (Invitrogen) LPS (100 ng/mL), PAM3
(Pam3CSK4, 1 mg/mL), R848 (350 nM), POLYIC (50 mg/mL),
CPG (0.5 mM) and FLAST (20 mg/mL). All ligands were culture-
tested and endotoxin free. DC2.4 cells were treated similarly.
RNA Extraction
Total RNA was isolated from treated and untreated cells using
Trizol reagent. RNA was quantified by NanoDrop ND-1000
spectrophotometer, and quality was evaluated with Agilent RNA
Figure 1. Expression of MARCO receptor in splenic and bone marrow-derived DC. (A) MARCO gene expression was determined in BMDC
at various time points following treatment with various TLR agonists. Raw data from gene expression dataset GSE17721 [20] were analyzed to extract
MARCO expression values. Data were processed for normalization using the RMAexpress tool and gene annotation using the MeV software. (B)
MARCO expression as determined by RT-PCR is shown in TLR agonist-activated DC2.4 cell line (left panel), splenic DC from WT and MARCO
2/2 DC
from 3 individual mice (middle panel), and TLR agonist-activated splenic DC (right panel). GAPDH expression was used for normalization. Data shown
as Mean 6 SD from triplicates. *P,.05; **P,.01.
doi:10.1371/journal.pone.0104148.g001
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and RIN determined by 2100 Expert software.
Gene Expression Profiling
Gene expression was assessed using Affymetrix (Santa Clara,
CA) GeneChip Mouse Genome 430 2.0 arrays. 15 mg cRNA was
fragmented and hybridized to arrays’ according to the manufac-
turer’s protocols as described previously [19]. The quality of
Figure 2. Differentially expressed genes in WT and MARCO
2/2 DC cells. High purity DC preparations were isolated from splenocytes from 5–
6 mice per group by positive selection with CD11c antibody and incubated overnight in media containing PBS or LPS (100 ng/ml). Total RNA was
extracted and subjected to gene expression profiling. (A) Venn diagrams showing the numbers of genes that differ in expression by a factor of at
least 2 between WT and MARCO
2/2 DC without and with LPS (left diagram), and numbers of genes that are differentially upregulated (middle
diagram) or downregulated (right diagram) in WT and MARCO
2/2 DC following LPS exposure. (B) Top 15 differentially expressed genes that
characterize MARCO vs. WT, WT_LPS vs. WT, MARCO_LPS vs. MARCO, and MARCO_LPS vs. WT_LPS. Data shown represent fold change of gene
expression.
doi:10.1371/journal.pone.0104148.g002
Figure 3. Major DC Signaling Pathways and Functions are affected by MARCO. Sets of differentially expressed genes (fold change of 2 or
higher) between different DC conditions were uploaded onto Ingenuity Pathway Analysis and corresponding signaling pathways were predicted. (A)
MARCO vs. WT. (B) MARCO_LPS vs. WT_LPS. Statistical significance was set at 2log P=2 (Left Y Axis). The Ratio on the right Y axis represents the
fraction of genes that are differentially expressed in our dataset that fall within a specific pathway out of the total number of genes that contribute to
that pathway. Similarly, Biofunction analysis was performed for MARCO vs. WT (C) and MARCO_LPS vs. WT_LPS (D). Statistical significance was set at
activation z-score=2. Scores higher than 2 indicate activated functions, whereas scores lower than 22 indicate inhibited functions.
doi:10.1371/journal.pone.0104148.g003
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values, percent present calls, scaling factors, and 39/59 ratio of b-
actin and GAPDH. Data were extracted from CEL files and
normalized using RMAexpress (http://rmaexpress.bmbolstad.
com/) and annotated using MeV software (http://www.tm4.
org/mev.html). Differentially expressed genes between different
conditions were determined using a fold change threshold of 2.
‘‘The data generated have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO Series
accession number GSE55068 (http://www.ncbi.nlm.nih.gov/gds/
?term=GSE55068)’’.
Data showing MARCO expression in response to TLR ligation
in bone marrow-derived DC were extracted from the gene
expression dataset GSE17721 [20]. CEL files were downloaded
from the NCBI Gene Expression Omnibus (GEO) and processed
for normalization using the RMAexpress tool and gene annotation
using the MeV software.
Figure 4. Comparison of Upstream Regulator status between WT and MARCO
2/2 DC. Differentially expressed genes (fold change of 2 or
higher) were processed through Ingenuity Pathway Analysis to predict the downstream regulators whose activation status was affected by the
absence of MARCO in resting cells (A) or LPS-challenged cells (B). The Venn diagram in (C) shows the transcription factors that respond to LPS in WT
(WT_LPS) and MARCO
2/2 (MARCO_LPS) DC. Transcription factors that reached the significant activation z-score of 22o r+2 are shown. (D) Shown
are representative microRNAs that reached the significant activation z-score of 22o r+2. The IPA tool predicts a microRNA to be activated when
enough differentially downregulated genes fall among the targets for this microRNA. The inhibition status is attributed when the opposite occurs.
doi:10.1371/journal.pone.0104148.g004
Figure 5. Involvement of MARCO in the TGF-b signaling pathway. Expression of differentially expressed genes in our dataset that are known
to be regulated through by SMAD transcription factors within the TGF-b signaling pathway was measured by RT-PCR in resting WT and MARCO
2/2
DC. *P,.05, **P,.01. Data show the mean 6 SD of 3 WT and 3 MARCO
2/2 samples where each sample represents a pool of 3 splenocyte
preparations.
doi:10.1371/journal.pone.0104148.g005
Role of MARCO in Dendritic Cell Activation
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e104148Pathway and Functional Analysis
Genes that showed a fold change in expression of at least 2 were
uploaded onto the Ingenuity Pathways Analysis tool (Ingenuity
Systems, http://www.ingenuity.com). IPA applications were used
to generate and assess statistically relevant biofunctions, canonical
pathways, networks and changes in transcription factor status
associated with the differentially expressed gene profiles extracted
from the transcriptome data.
Pathway and Functional analyses of the differentially expressed
genes were performed using the commercial systems biology
oriented package Ingenuity Pathways Analysis (www.ingenuity.
com). Ingenuity Pathway Analysis Tool was used to calculate the
p-value with Fisher’s Exact Test for each pathway and functions.
The p-value measures the likelihood of random chance for the
observed association between a specific pathway/function in the
dataset, by also considering the total number of Functions/
Pathways/Lists of eligible genes in the dataset and the Reference
Set of genes (those which potentially could be significant in the
dataset). In case of interactive networks, all the identified genes
were mapped to genetic networks available in the Ingenuity
database and were ranked by the score. The Score (2log P value)
is calculated using Fisher’s Exact Test and indicates the likelihood
a gene will be found in a network due to random chance. For
example, if a network achieves a score of 2, it has at least 99%
confidence of not being generated by chance alone.
Transcription Factor and miRNA Profiling
Ingenuity’s Upstream Regulator Analysis is a tool that allows
prediction of the activation status of various regulators, including
transcription factor and micro-RNAs, based on genome-wide
differentially expressed gene signature. This tool predicts which
transcriptional regulators and micro-RNAs are involved and
whether they are likely to be activated or inhibited. The activation
status of a given regulator is predicted through a calculated
activation z-score where z.2 predicts activation and z,22
predicts inhibition.
Quantitative Real-Time PCR (qRT-PCR)
Validation of differentially expressed genes and genes belonging
to specific pathways and functions was performed by RT-PCR.
200 ng of high quality RNA samples were reverse transcribed to
first strand cDNA and 1 ml cDNA was used for each RT-PCR
reaction. Samples were performed in triplicates. SYBR Green
PCR Master Mix (Applied Biosystems, Foster City, CA) was used
for two-step real-time RT-PCR analysis on an Applied Biosystems
StepOnePlus Real Time PCR instrument. Primers’ sequences
were designed using the rpimer3 tool (http://bioinfo.ut.ee/
primer3-0.4.0/primer3/). Expression value of the targeted gene
in a given sample was normalized to the corresponding expression
of GAPDH. The 2
–DDCt method was used to calculate relative
expression of the targeted genes.
Statistical analysis
Student’s t test (unpaired, two-tailed) was calculated using
GraphPad Prism to determine significance levels between groups
and treatments for all RT-PCR measurements. Data are presented
as mean 6 SEM or SD. Differences were considered significant
when p,.05.
Ethics Statement
All experimental procedures involving animals were approved
by the Institutional Animal Care and Use Committee at Beth
Figure 6. Validation of highly differentially expressed genes between WT and MARCO
2/2 DC in response to TLR challenge. DC were
cultured overnight in the absence and presence of different TLR agonists. RT-PCR was performed to measure gene expression. *P,.05 for MARCO
2/2
vs. WT DC. Data show 3 WT and 3 MARCO
2/2 samples where each sample represents a pool of 3 splenocyte preparations.
doi:10.1371/journal.pone.0104148.g006
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injury to animals was limited to that which was unavoidable in the
conduct of scientifically valuable research and that analgesic,
anesthetic, and/or tranquilizing drugs were used where indicated
and appropriate to minimize pain and/or distress to animals. All
personnel performing the animal procedures/manipulations/
observations described in this protocol are technically competent
and have been properly trained to ensure that no unnecessary pain
or distress was caused to the animals as a result of the procedures/
manipulations.
Results
Basal and induced MARCO expression in bone marrow-
derived and mature splenic dendritic cells
To gain insight into the regulation of MARCO expression in
response to DC activation, we analyzed publicly available gene
expression profiling data [20]. In silico analysis revealed similar
expression kinetics in mouse bone marrow-derived dendritic cells
(BMDC) in response to all TLR agonists investigated. In this data
set, MARCO mRNA was detectable starting at 4 h and peaked at
16 hours following exposure to agonists of TLR1/2, TLR4,
TLR7/8 and TLR9, but not TLR3 (Figure 1A). We extended
these findings experimentally, and found that the DC2.4, a mouse
BMDC cell line, did not increase expression of MARCO in
response to the TLR-3 agonist PolyIC, but expression of MARCO
was increased by the other TLR agonists (Figure 1B, Left Panel).
Mature splenic DC from adult C57BL/6 mice, purified using
positive selection and confirmed by flow cytometry to express the
CD11c, MHC-II and CD80 markers, express low, yet detectable
levels of MARCO in the absence of stimulation as detected by
RT-PCR, while MARCO
2/2 mice show no expression (Fig-
ure 1B, Middle Panel). Following in vitro challenge with TLR
agonists, PolyIC and Flagellin, these cells failed to induce
MARCO expression, while LPS, CpG, Pam3 and R848 induced
significant levels of expression, compared to the PBS-treated cells
(Figure 1B, Right Panel). Together these results indicate that
expression of MARCO is induced in numerous DC models by
certain TLR agonists.
Differential gene expression in WT and MARCO
2/2 DC
indicate altered phenotype and response characteristics
To investigate the effect of basal MARCO expression in splenic
DC, we first profiled genome-wide gene expression of resting DC
to identify inherent differences between WT and MARCO-
deficient cells. A total of 219 genes showed differential expression
by at least 2-fold between WT and MARCO
2/2 DC (Figure 2A).
Within these data, we found changes in genes related to the
extracellular matrix and plasma membrane components. Highly
significant upregulation of multiple collagen transcripts type I, II,
IV, V and VII were noted in MARCO
2/2 cells. Upregulation of
matrix Gla protein (20.3-fold), osteoblast specific periostin (11-
fold), osteonectin Sparc (6-fold), BMP2, fibronectin 1 (5.9-fold),
and fibrillin (2.6-fold), lectin (3.4-fold), tissue inihibitor of matrix
metalloproteinase inhibitor 1 (2.6-fold) and MMP2 (2.1-fold) were
observed in MARCO
2/2 over WT cells. Likewise, an interesting
repertoire of transcripts of plasma membrane proteins was
upregulated in MARCO
2/2 at steady state, namely CD16a
Figure 7. Differential expression of immune and inflammatory marker genes between WT and MARCO
2/2 DC in response to TLR
agonist challenge. DC were cultured overnight in the absence and presence of different TLR agonists. RT-PCR was performed to measure gene
expression. (A) Basal expression in WT and MARCO
2/2 DC in the absence of TLR ligation. *P,.05. Data show the mean 6 SD of 3 WT and 3 MARCO
2/2
samples where each sample represents a pool of 3 splenocyte preparations. (B) Gene expression ratio for MARCO/WT was calculated to reveal the
magnitude of MARCO’s contribution for each individual gene across all TLR agonists.
doi:10.1371/journal.pone.0104148.g007
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endothelial cell adhesion molecule (2.1-fold), and caveolin 1 (2.3-
fold). There was decreased expression of CD209 (DC-SIGN) in
MARCO
2/2 cells by nearly 4.5 folds, and reduced CD55
(complement regulated gene) by nearly 3-fold (Figure 2B).
The set of 219 differentially expressed genes were further
organized into functional groups of biological functions and
signaling pathways using the Ingenuity Pathway Analysis package
(www.ingenuity.com). The Complement pathway was the most
significantly altered among the differentially expressed genes
between MARCO
2/2 and WT DC. Significant differential
expression was also observed in genes involved in caveolar-
mediated endocytosis, tight junction signaling, cytoskeleton
signaling, leukocyte extravasation signaling, and calcium signaling,
among others (Figure 3A).
Figure 8. Impact of MARCO on DC responsiveness to different TLR agonists. RT-PCR data from Figure 7 was plotted using the
Ligand/Ctrl ratio to reveal the contribution of the presence and the impact of the absence of MARCO on TLR-induced inflammatory
gene signature in WT and MARCO
2/2 DC, respectively. The Ligand/Ctrl Ratio was calculated for each gene to allow comparisons between WT
and MARCO
2/2 DC across all TLR agonists.
doi:10.1371/journal.pone.0104148.g008
Figure 9. Impact of MARCO on TLR gene expression in DC. TLR2-9geneexpressionwasdeterminedinunstimulatedsplenicWTandMARCO
2/2
DC. Data show the mean 6 SD of 3 WT and 3 MARCO
2/2 samples where each sample represents a pool of 3 splenocyte preparations. *P,.05. GAPDH
expression was used for normalization.
doi:10.1371/journal.pone.0104148.g009
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and MARCO
2/2 DC
We next evaluated the impact of MARCO deficiency on DC
activation, using LPS as a surrogate for Gram(2) bacterial
infection or adjuvant-supplemented vaccination. DC were treated
with LPS or vehicle overnight. The time point was chosen for
optimal induction of most LPS inducible genes as deduced from
available gene expression profiling data, as well as to specifically
evaluate the relatively early response of DC to LPS stimulation in
presence and absence of MARCO. Following this activation, 652
gene transcripts were differentially expressed by 2-fold or greater
in MARCO
2/2 over WT, nearly 3 times higher when compared
to the 219 genes that changed in the absence of LPS (Figure 2A,
Left Venn Diagram), including 100 shared transcripts. The 652
gene set includes many genes that have been shown to play key
roles in DC biology (Figure 3B, 3C & 3D). Pathway analysis of
differentially expressed genes revealed deregulations in Rho A
signaling pathway, leukocyte extravasation signaling, actin cyto-
skeleton signaling, clathrin-mediated endocytosis signaling, pattern
recognition receptor function, PKA signaling, NF-kB activation
and signaling, Rho family GTPases signaling, FCcR-mediated
phagocytosis, complement system, DC maturation, LPS-induced
MAPK signaling, integrin signaling, IL-6 signaling, among others
(Figure 3B). It is noteworthy that genes related to pattern
recognition receptors in bacterial infection were also within this
category of highest significance, supporting the validity of the
comparison. Furthermore, comparison of the biofunctional
analysis for the non-stimulated versus stimulated MARCO
2/2
over WT revealed interesting features, presented in Figures 3C &
3D. Functions identified as cellular movement, immune cell
trafficking, and inflammatory response are predicted to be
activated in unstimulated MARCO
2/2 DC. Of note, the cluster
of genes responsible for cell movement were upregulated in
MARCO
2/2 cells over WT cells in unstimulated conditions,
whereas WT cells showed upregulation of this class of genes over
the MARCO
2/2 following LPS exposure, implying that MARCO
is involved in LPS-induced cell migration.
Additionally, we enumerated clusters of genes that are
differentially expressed in WT and/or MARCO
2/2 DC under
activating conditions. Our data suggest that the presence of
MARCO in DC (i.e. WT phenotype) correlates with upregulation
and downregulation of 389 and 877 genes, respectively, while its
absence results in upregulation and downregulation of 524 and
219 genes (Figure 2A, Middle and Right Venn Diagrams).
Together, this data suggests an involvement of MARCO in
LPS/TLR4-induced regulation of 2009 genes.
MARCO confers a distinct transcriptional factor profile to
DC regardless of their activation state
The dramatic differences in gene expression between MARCO
sufficient and deficient DC suggests major alterations take place at
the level of transcription factors. We used Ingenuity’s Upstream
Regulator Analysis tool to unravel transcription factors that had
significant perturbations. As evident in Figure 4, presence and
absence of MARCO in DC resulted in distinct transcription factor
activation status in both steady state (Figure 4A) and following
LPS activation (Figure 4B). Interestingly, NF-kB1A, an inhibitory
member of proinflammatory transcription factor NF-kB family, is
down-regulated in MARCO
2/2 cells following LPS stimulation,
in comparison to WT. This could imply decrease in the regulatory
component I-kB, and conversely, an increase in the pro-
inflammatory transcription factor engagement within the
MARCO
2/2 cells. This appears to be the case indeed in the
non-stimulated MARCO
2/2 cells where NF-kB complex gains
prominence over WT cells.
When looking at the transcription factor subsets that are
affected in WT and MARCO
2/2 DC following LPS activation,
one can see genotype-specific profiles, with 17 factors affected
exclusively in WT, 25 factors affected exclusively in MARCO
2/2,
and 21 overlapping factors that include 6 members of the
Interferon Regulatory Factor (IRF) family (Figure 4C).
Next, we used Ingenuity Pathway Analysis to predict the status
of microRNAs that regulate MARCO-driven differential gene
expression. MicroRNAs are important regulators that modulate
gene expression and thereby influence effector cell function of
immune cells, including DC [21]. In the absence of MARCO, and
under resting conditions, one single perturbation was predicted
that inhibits miR-29b-3p and potentially other micro-RNAs that
share the same target specificity. These micro-RNAs regulate
genes that were down-regulated in MARCO-deficient DC,
including COL1A1, COL1A2, COL3A1, COL4A1, COL4A2,
COL5A2, FBN1 and SPARC (Figure 4D). When WT DC were
challenged with LPS, 10 micro-RNAs were predicted to be
activated (z score .2, data not shown), including miR-155-5p
illustrated in Figure 4D. MARCO
2/2 DC, in contrast, showed
only 2 changes, with activated miR-210 and inhibited miR-122-5p
in response to LPS (Figure 4D).
MARCO deficiency leads to perturbations in the TGF-b
pathway
Equally interesting is the fact that the Smad family of
transcription factors was heavily represented as differentially
altered in the control sets (Figure 4). In our experiments,
unstimulated MARCO
2/2 cells showed activated Smad-2/3-
Smad-4 axis, with significant enhancement of Smad-1, Smad-4
and Smad-3, and a concomitant inactivation of Smad-7
(Figure 4A). Conversely, Smad-7 is activated in LPS-stimulated
MARCO
2/2 cells in comparison with stimulated WT cells
(Figure 4B). Therefore, we sought to further validate this in silico
prediction. We chose a panel of Smad-3- and Smad-7-responsive
genes through IPA analysis and compared their expression levels
by RT-PCR in the presence or absence of MARCO in non-
activated cells. The data show a significant increase in expression
of FPR2, ITGB5, COL1A2 and MMP2 that occurred in
MARCO
2/2 DC, whereas a decrease in ACTG2, BMP2, CTGF,
and DCN is noted (Figure 5).
MARCO exerts differential effects on TLR-induced DC
activation
Our in silico analysis revealed inherent differences in gene
expression between WT and MARCO
2/2 DC, and clearly
demonstrates an amplifying role for LPS activation on these
differences. This suggests an important role for MARCO on DC
in the context of proinflammatory insults such as LPS challenge.
In light of these findings and the previously reported interactions
of MARCO with members of the TLR family on macrophages,
we sought to examine the role of MARCO in DC responsiveness
to a panel of TLR agonists. This in vitro model, where synthetic
surrogates of known natural TLR ligands are used to challenge
DC, closely recapitulates exposure to bacterial, viral and fungal
infection, and equally emulates DC exposure to TLR-targeted
adjuvants in the context of active immunization.
DC were cultured overnight in the absence or presence of TLR
agonist doses that were shown to induce IL-6 expression under
similar experimental conditions (data not shown). RT-PCR was
first used to quantify the expression level of a set of genes that were
Role of MARCO in Dendritic Cell Activation
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magnitude of their differential expression. In the latter category,
the cell surface receptor DC-SIGN (CD209) offered an interesting
trend across the different TLR agonist treatments. At steady state,
WT and MARCO
2/2 DC expressed similar amounts of CD209A
and CD209B mRNA transcripts. Upon activation, differences
between WT and MARCO
2/2 DC were observed in response to
LPS, CPG and PAM3. FCGR4, also known as Fc Receptor-like 3
(Fcrl3) and CD16-2, is absent in WT DC but present at a low level
in MARCO
2/2 DC. Upon activation, its differential expression
varies between agonists. Similar to FCGR4, Cathepsin E (CTSE)
is only present in non-activated MARCO
2/2 DC. Interestingly,
while the CTSE gene in MARCO
2/2 DC responded to all TLR
agonists to various extents, WT DC only responded to PAM3 and
FLAST. Conversely, Histone deacetylase 5 (HDAC5) is only
expressed in WT DC and its response to TLR agonists is overall
weak and variable (Figure 6).
RT-PCR quantitation was next performed to assess a panel of
immune and inflammatory marker genes. We found that all the
genes tested were expressed at a relatively low level in non-
activated DC regardless of the presence of MARCO, albeit with a
tendency for slightly higher expression in the WT (Figure 7A).
Interestingly, the challenge of WT and MARCO
2/2 DC with
TLR agonists elicited responses that widely varied in magnitude
depending on the agonist and target gene. This trend is more
evident when data are plotted as a MARCO/WT expression ratio
to highlight the impact of MARCO deficiency (Figure 7B). Most
ratios are lower than 1, indicating that MARCO deficiency causes
a decrease in gene expression, suggesting thus a positive role for
MARCO in regulating expression of these genes.
However, because inherent differences in expression of several
genes were observed in the absence of agonists (Figure 7A), we
sought to determine the effect of MARCO on DC responsiveness
to each TLR agonist. To this end, we calculated the ratio of
ligand-induced expression value to control expression value (i.e. in
the absence of ligand) for each individual gene in both WT and
MARCO
2/2 DC. Using this ratio led to a number of interesting
observations; First, LPS seems to augment or suppress gene
expression depending on the gene, with the suppression preferen-
tially affecting WT DC. Second, all other TLR agonists enhance
expression of all genes, with the exception of STAT5A, regardless
of the MARCO status. Last, while overexpression of some genes,
e.g. STAT5A, IL1B, CCL22, NFKB1, and CDKN1A, is more
prominent in MARCO
2/2 DC, other genes like IL12B and IRF8
are preferentially overexpressed in WT DC (Figure 8).
MARCO effects are not due to differential TLR expression
Available data suggest cooperativity between scavenger recep-
tors and TLRs [11]. Hence, differences in expression of TLRs on
the surface of DC in the absence and presence of MARCO might
skew this cooperativity. Therefore, to ascertain that the observed
effects are not due to intrinsic differences in TLR expression
between WT and MARCO
2/2 DC, we quantitated RNA
transcripts for TLR1-9 in untreated DC from both genotypes.
Interestingly, TLR-3 is the only member of the TLR family that is
differentially expressed, showing a significant decrease in the
absence of MARCO, whereas a trend of increased TLR-2 and
TLR-9 expression in MARCO
2/2 DC did not achieve statistical
significance (Figure 9).
Discussion
In the present study we show that spleen DC express the
receptor MARCO and MARCO expression is inducible through
TLR ligation. Interestingly, among all TLR agonists we tested,
Poly-IC is the only one that failed to trigger MARCO expression,
suggesting TLR-3-induced signaling is not involved in regulating
MARCO expression in spleen DC. A similar finding was reported
previously using bone marrow-derived dendritic cells [20,22] and
macrophages [23]. Because TLR-3-mediated signaling, unlike
signaling through other TLRs, does not require the adaptor
MyD88 [24], our finding also suggests a key role for MyD88 in
inducing MARCO expression.
At the genome-wide gene expression level, MARCO expression
on resting DC correlates with marked divergences between WT
and MARCO
2/2 DC. Interestingly, these divergences become
even more prominent following LPS treatment, suggesting an
important role for MARCO in TLR4-induced signaling. Further-
more, significant differences are observed in expression of pro-
inflammatory markers in response to several TLR agonists,
suggesting MARCO’s contribution to cell signaling might be a
critical component of a feedback loop that is common to all TLRs
on DC.
While many observations emerging from our in silico analysis
and RT-PCR validation deserve careful interpretation, three of
them may be of special interest and therefore will be addressed
here. First, particularly important is our observation that
alterations in the activation status of Smad proteins, the main
effector regulators of the TGF-b pathway, are taking place in
MARCO
2/2 DC under both resting and activating conditions.
Notably, LPS challenge reverses the activation state of SMAD
proteins observed in resting cells. These predicted dysregulations
in the TGF-b signaling pathway were reflected in significant
expression changes of many TGF-b-regulated genes, as evidenced
by our RT-PCR measurements. This observation is of paramount
importance because TGF-b pathway is crucial in determining DC
phenotype and T cell activation [25]. TGF-b prevents autoim-
munity by maintenance of immature DC in a tolerogenic state.
The tolerogenic effect of immature DC is due to soluble TGF-b
secreted by Regulatory T cells [26]. Additionally, TGF-b secreted
by tumor cells and tumor-associated macrophages tolerizes DC in
the tumor and draining lymph nodes thus hampering anti-tumor
immunity [27], a powerful mechanism of immune tolerance to
tumors that could be reversed by TGF-b or TGF-b receptor
blockade [28]. Second, MARCO seems to exhibit an inhibitory
effect resulting in lower production of IL-12b and CDKN1A in
WT DC. IL-12 plays a crucial role in Th1 differentiation [29],
thus driving anti-viral and anti-tumor adaptive responses [30].
Interestingly, the effect of MARCO on IL-12b expression might
also extend to the production of IL-23. IL-12 and IL-23 share the
IL-12b chain [31]. IL-12 promotes Th1 immunity and IL-23
promotes Th17 immunity, and it has recently become apparent
that the balance between IL-12 and IL-23 is very important in
immune regulation (Reviewed in ref. [32]). In a recent study,
Komine et al. generated a new MARCO-deficient mouse to
address the role of MARCO in DC [33]. This study showed low
expression of MARCO in resting BMDC, with a significant
increase following challenge with LPS or tumor lysate. It also
showed an increased motility of MARCO
2/2 DC. However,
there were no differences in the release of IL-12, IL-10 or TNF-a
between WT and MARCO
2/2 BMDC following LPS treatment,
which might reflect one of the intricate differences between splenic
and bone-marrow derived DC. Finally, while the effect of
MARCO on the responsiveness of DC to agonists that recognize
cell surface TLRs (TLR-2, 4, 5, and 6) could be attributed to
overlapping specificity and affinity to the agonist and to physical
interaction between the receptors, the impact observed on the
responsiveness to cytosolic TLRs (TLR-3, 7, and 9) is intriguing.
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demonstrate that macrophage SR-AI/II and MARCO recognize
and mediate rapid internalization of agonists to endosomal TLR-3
and cytosolic NOD2 (nucleotide-binding oligomerization domain)
and NALP3 (NACHT domain-, leucine-rich repeat-, and pyrin
domain-containing protein 3) to elicit robust macrophage
responses. Conversely, SR-AI/II and MARCO also internalize
TLR-4 ligands, thus attenuating TLR4-mediated responses [14].
Our observations could also be due to an effect of MARCO on
mechanisms inherent to cytosolic TLR function. In fact, TLR-3, 7
and 9 must traffic from the endoplasmic reticulum (ER) to
endolysosomes before responding to ligands. This trafficking is
facilitated by UNC93B1, a multi-pass transmembrane protein
localized to the ER [34,35]. UNC93B1 is not required for
responses by surface localized TLRs such as TLR2 and TLR4
[36]. Although our work does not address these two mechanisms
in DC, it remains a plausible explanation for the observed
MARCO’s wide effects that span the entire TLR family.
Although this work highlights the role of MARCO in DC
activation induced by single microbial compounds, we recognize
that pathogens express several TLR agonists that may concom-
itantly engage more than one TLR. For example, selected
combinations of TLR agonists have been shown to polarize T
cells towards a Th1 phenotype [37]. In such a scenario, one could
anticipate that MARCO’s role would be even more significant as it
interacts and interferes with signals elicited by various TLRs.
Collectively, our gene expression profiling of MARCO sufficient
and deficient mature DC and RT-PCR validation efforts identify a
prominent involvement of MARCO in TLR-induced inflamma-
tory responses. MARCO’s role seems to span all TLRs, suggesting
its implication in the upstream arm of TLR signaling cascade.
These new findings add to our understanding of the nuances of
DC function in the context of immune regulation by TLR and
other pattern recognition receptors. The wide range of genes,
pathways and functions that are affected by MARCO in DC
warrants more focused future investigation, and opens the
prospect of therapeutically targeting MARCO receptor in the
hope of ameliorating autoimmune disease, infections and cancer
immunotherapy.
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